# Three Peptides Compared on How They Were Studied

> Comparing the Evidence: Retatrutide, BPC-157 and Thymosin Alpha-1 — Savvy Peptides — A side-by-side appraisal of three Research Peptide Fundamentals research peptides on design rather than pharmacology: control, blinding, sample size, endpoint type, replication and confirmatory status.

**RESEARCH PEPTIDE FUNDAMENTALS / MATRIX**

The same six appraisal dimensions applied to retatrutide, BPC-157 and thymosin alpha-1 — which produces a very different ranking from comparing their mechanisms.

## The short version

Most comparisons of research peptides line up what each one does. This one lines up how well each one has been tested, which is a different question and often a more useful one. The six things being compared are simple. Was there a comparison group? Did anyone know who was getting what? How many people took part? Was the thing measured something that matters directly, like whether people lived, or a stand-in like a blood test? Has anyone repeated it? And has the final, confirming study been done? On those measures the ranking flips. Retatrutide has excellent studies that have not finished. Thymosin alpha-1 has the single best-built study on this site, and it came back negative. BPC-157 has the largest pile of research and the weakest human evidence in the group. Quality of testing and volume of literature are not the same thing.

## The evidence-quality matrix

| Appraisal dimension | Retatrutide | BPC-157 | Thymosin Alpha-1 |
| --- | --- | --- | --- |
| Strongest published human design | Randomised, double-blind, placebo-controlled phase 2; one trial also active-controlled [4][5] | Uncontrolled first-in-human safety pilot [8] | Multicentre, double-blinded, randomised, placebo-controlled phase 3 [13] |
| Largest human sample | 338 adults [4] | 2 adults [8] | 1,106 adults [13] |
| Blinding | Double-blind throughout [4][5][6] | None | Double-blind [13]; the earlier trial was single-blind [17] |
| Control arm | Placebo, plus an active comparator in type 2 diabetes [5] | None [8] | Placebo [13] |
| Primary endpoint type | Surrogate markers: body weight, HbA1c, liver fat [3][4][5] | Safety biomarkers only [8] | A hard clinical event: 28-day all-cause mortality [13] |
| Dose-response demonstrated | Yes, ordered across four ascending doses [3] | In rodents only [12] | Not the design question in the pivotal trial |
| Confirmatory trial status | Phase 3 ongoing [1] | Never conducted [9] | Completed, and null [13] |
| Dominant evidence species | Human [3][4][5][6][7] | Rat, dog, chick membrane, cultured cells [10][11][12] | Human [13][15][17] |
| Independent replication | Industry-run programme; confirmation pending [1] | Foundational literature concentrated in one research group [9] | Replicated at higher rigour; the signal did not hold [13][17] |
| The most useful question to ask next | Does the marker predict the outcome? | Has anyone unrelated repeated this in a person? | Which of the two trials is being quoted? |

## Control and blinding

A control arm answers the question "compared with what?", and without one, almost nothing observed can be attributed to the compound. Retatrutide's trials all carry a placebo arm, and the phase 2 type 2 diabetes trial carries an active comparator as well [5] — a stronger construction, because it tests not whether the drug does something but whether it does more than an existing option. Thymosin alpha-1's pivotal trial is placebo-controlled [13]. The BPC-157 human record has no control arm anywhere in it [8].

Blinding then determines how much the control arm is worth. The comparison available here is unusually direct, because thymosin alpha-1 was tested twice in the same condition on the same primary endpoint at two levels of blinding. The single-blind trial, with 361 patients, reported 26.0 percent 28-day mortality against 35.0 percent in controls [17]. The double-blind trial, with 1,106 patients, reported 23.4 percent against 24.1 percent [13]. Both were randomised and multicentre. The most economical explanation for the difference is not that the peptide stopped working; it is that unblinded clinical judgement in a critical-care setting is a powerful source of differential care between arms, and that removing it removed the effect.

## Sample size, and what a number can detect

The human sample sizes across this site span nearly three orders of magnitude: 2 [8], 72 [6], 98 [3], 281 [5], 338 [4] and 1,106 [13]. Sample size is not a measure of prestige. It is a measure of what a study is capable of noticing, and reading it that way makes several papers easier to place.

A two-person report [8] is capable of noticing effects so common they would appear in nearly everyone exposed and nothing else — which is precisely the job of a first-in-human safety pilot and a reasonable design for that purpose. A 72-person phase 1b trial [6] is sized to characterise pharmacokinetics and tolerability, which is why its efficacy figure arrives with a confidence interval wide enough to make the point itself. A trial of several hundred [4][5] can detect a large efficacy difference on a marker that moves reliably. A trial of a thousand-plus [13] is sized to detect a plausible difference in a rare-ish binary event such as death within 28 days, which requires far more participants than a continuous marker does.

The corollary matters more than the rule: a study that fails to find an effect it was never large enough to detect has not shown the effect is absent. The distinction between an underpowered study and a genuine null is entirely a matter of design, not of result.

## Endpoints: a marker or the thing itself

This is where the three compounds separate most sharply, and where the ranking most surprises a reader coming from the pharmacology.

Retatrutide's most impressive figures are all surrogates. A relative liver-fat reduction of 82.4 percent with 86 percent of participants reaching normal liver fat [3], a body-weight change of -24.2 percent [4], an HbA1c reduction of 2.02 percent [5] — every one of these is a measurement chosen because it moves quickly, quantifies precisely and can be captured inside a trial of practical length. Surrogates are legitimate and necessary; they are also a bet that moving the marker moves the outcome, and that bet has to be settled by a separate trial powered for events. Retatrutide's has not reported.

Thymosin alpha-1's pivotal trial measured death [13]. There is no interpretive gap between the endpoint and what anyone cares about, which is exactly why the null carries the weight it does. A negative result on a hard endpoint in a well-powered blinded trial is among the most informative things a literature can contain, and it is systematically under-cited relative to positive results on markers.

BPC-157's human record measures neither. The pilot reported cardiac, hepatic, renal, thyroid and glucose biomarkers and observed no changes [8] — safety parameters, not efficacy endpoints of any kind. The rodent work does report outcomes, such as an ulcer-formation inhibition ratio of 45.7 to 65.6 percent [12], but those are outcomes in rats.

## Replication, independence and who ran the study

The three compounds illustrate three distinct provenance situations, and they are not equivalent.

Retatrutide's trials are a sponsor-run development programme [1][4][5][6]. The designs are strong and the reporting is detailed, and the appropriate response is not suspicion but specificity: read the pre-registered protocol, check whether the reported primary endpoint is the registered one, and note that confirmation is still pending.

BPC-157's literature is concentrated in a single research group and its collaborators, which newer reviewers flag explicitly [9]. This is a structural weakness rather than an allegation. Independent replication exists to catch systematic errors that everyone inside one programme shares — an assay quirk, a model artefact, an analytic habit — and a literature that has never left its originating group has never been exposed to that check.

Thymosin alpha-1 has the outcome that replication exists to produce. An earlier signal was tested by a larger, better-blinded, independently conducted trial and was not confirmed [13][17]. That is not a failure of the scientific process; it is the process working, and it is the reason the earlier positive trials and the meta-analyses built on them can now be read at their correct weight rather than at their apparent one.

---

Savvy Peptides is a critical-appraisal digest — it grades the design of the peptide studies it summarises, and a graded reading of the literature is not a clinic, a vendor, or medical advice.